A total of 85 allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis treated with amphotericin B lipid complex (ABLC) were identified from the Collaborative Exchange of Antifungal Research (CLEAR) database. Of these patients, 78% (66/85) presented with pulmonary aspergillosis. Graft-versus-host disease (GVHD) was present in 24 of 85 patients. The response rate to ABLC was 31% (26/85) overall and 21% (5/24) in patients with GVHD. The overall response rate to first-line ABLC treatment was 41% (11/27). Four of nine (44%) patients with GVHD responded to first-line treatment with ABLC, while only one of 13 (8%) responded to ABLC as second-line therapy. Five of 18 (28%) and four of 14 (29%) patients, respectively, responded to sequential or concurrent treatment with ABLC and itraconazole. None of seven patients responded who continued receiving itraconazole after the start of ABLC therapy. At the end of ABLC therapy, serum creatinine had doubled in 12% of patients (10/85), and 2% (2/85) had developed a requirement for dialysis. These data suggest that ABLC, especially when administered as first-line therapy, can result in clinical response even in the most immunocompromised patients, that is, HCT recipients with GVHD, with minimal effects on renal function.
geneic; aspergillosis Hematopoietic cell transplant (HCT) recipients are at great risk of developing invasive aspergillosis (IA), 1,2 with high mortality rates. [2] [3] [4] In particular, receipt of an HCT from a mismatched or unrelated donor, as well as graft-versus-host disease (GVHD), have previously been identified as risk factors for IA. 2 Amphotericin B desoxycholate (AmB), historically the most effective broad-range systemic antifungal agent, 5 is known for dose-limiting nephrotoxicity. 6, 7 HCT recipients have been found to be particularly vulnerable to this complication. 6, [8] [9] [10] In the past 10 years, a number of new antifungal agents that are less nephrotoxic than AmB have been approved for use against aspergillosis including lipid formulation of AmB, the echinocandin caspofungin, and the extended-spectrum azole, voriconazole. Recently, voriconazole was shown to be superior to AmB as initial therapy in IA. 11 It is now considered the standard for initial therapy of IA. While the overall response rate to voriconazole was 52.8%, it was only 32.4% in HCT recipients.
The present retrospective report evaluates the effectiveness and renal safety of ABLC use in allogeneic HCT recipients with IA, and considers the potential advantage of first-line ABLC therapy in these patients.
Patients and methods

Compilation of the Collaborative Exchange of Antifungal
Research (CLEAR) registry and methods of data analysis have previously been described elsewhere. [12] [13] [14] A brief description is provided here.
The CLEAR database provides effectiveness and renal safety data for 3514 patients treated with ABLC from 1996 to 2000 at more than 160 institutions in the United States and Canada. Of the 634 clinically evaluable HCT recipients identified from the CLEAR database, 85 allogeneic HCT recipients with invasive infection only with one or more Aspergillus species were further considered for this report.
Patients were prospectively enrolled in the CLEAR program and data were collected retrospectively. Patients who had received at least four doses of ABLC for treatment of a proven or suspected fungal infection were eligible for enrollment in the database. Exclusion criteria were not available in the study guidelines. Based on pre-Health Insurance Portability and Accountability Act (HIPAA) regulations, patient charts were retrospectively reviewed and patient data collected on standardized case report forms after de-identification. During the study period, institutional review board consent for retrospective data collection was obtained at each study site. Mortality data were not collected for the entire study duration, and thus have not been analyzed in CLEAR.
Clinical outcomes, based on the clinical judgment of the principle investigator, were recorded on the data collection form according to the following guidelines: (1) Cured: clinical signs and symptoms of fungal infections absent; (2) Improved: clinical signs and symptoms of fungal infections improved; (3) Stable: no change in overall clinical findings compared to previous reporting period; (4) Deteriorated: clinical signs and symptoms of fungal infection worsened; (5) Indeterminate: clinical signs and symptoms of fungal infection insufficient to evaluate the outcome. For analysis purposes, patients with indeterminate outcomes or with missing clinical outcome records were considered unevaluable and excluded from analyses. In the present study, response rate was defined as the percentage of patients with clinical outcomes of cured or improved.
Actual duration of ABLC dosing (in days) was calculated as (last dose dateÀfirst dose date) þ 1 for each individual dose record. Average daily dose was calculated as (total dose/weight)/actual duration.
The infecting fungal pathogen was documented for each patient if identified, and sites of infection and diagnostic methodology used to identify the pathogen were also recorded. If a pathogen was not identified, 'suspected pathogen' was checked in the data collection form. Patients with documented Aspergillus infection in the lungs, central nervous system (CNS), sinuses and skin and one patient whose site of infection was missing were included in the analyses. Five patients with infection in the oropharynx alone or in conjunction with another unspecified site were excluded from analyses.
Investigators classified the rationale for ABLC therapy according to one or more of the following four categories, the first chosen category taking precedence: (1) refractory to prior antifungal therapy, (2) underlying renal disease, (3) intolerant of prior antifungal therapy, (4) no underlying renal disease and no prior antifungal treatment. Subsequently, during data analysis, the category of underlying renal disease was further subdivided based on prior exposure to antifungal therapy. This categorization enabled the analysis of data from patients who received ABLC as first-line vs second-line therapy.
Serum creatinine (S-Cr) values were collected only at the start and end of ABLC therapy. Predicted creatinine clearance (C cr ) was calculated from S-Cr values using the Cockcroft-Gault formula. 15 Median values and value ranges are presented for average daily dose, duration of therapy and renal function parameters where applicable. The significance of difference in proportions was determined by the w 2 or Fisher's exact test, as appropriate. Difference in continuous variables was detected using the nonparametric median test. All P-values were two-sided, and a value of Po0.05 was considered statistically significant. Data processing and statistical analyses were performed using SAS s System version 8.2 (SAS Institute, Cary, NC, USA), with a Microsoft Windows s 2000 or XP operating system.
Results
Of the 85 patients investigated in this study, 66% were male patients and 78% were Caucasian. Their median age was 40 years (range 4-70 years). Patients received a median daily ABLC dose of 4.6 mg/kg (range 0.6-10 mg/kg/day) for a median duration of 19 days (range 3-160 days). The median cumulative weight-adjusted dose was 76.6 mg/kg (range 8.4-519 mg/kg). The lungs were the predominant site of involvement in 78% of patients; the lungs alone were involved in 64% of patients, lungs plus CNS with or without other organ involvement in 7%, lungs plus sinuses in 5%, lungs plus other sites in 2%. Other major sites of involvement included the CNS alone (5%) and the sinuses alone (6%). Clinical response rates (defined as the proportion of patients with an outcome of cured or improved) are presented in Table 1 . The overall clinical response rate was 31% (26/85), while the subset of patients who developed GVHD had only a 21% response rate (5/24). Clinical response rates in patients who received ABLC as first-line vs second-line treatment are shown in Figure 1 . Table 1 Clinical response to ABLC treatment in allogeneic hematopoietic cell transplant recipients with invasive aspergillosis Clinical response Allogeneic HCT Overall, the response rate for first-line treatment (41%; 11/27) was higher than that for second-line treatment (29%; 15/52). Among patients who developed GVHD, four of nine (44%) responded to first-line treatment, while only 8% (1/13) responded to second-line treatment with ABLC. The neutrophil status of HCT recipients at the beginning of therapy and at the end of therapy is presented in Table 2 . The majority of patients (60/85, 71%) were never neutropenic. Furthermore, these were the patients who had the best response (38.3%). Those who initially were neutropenic but by the end of therapy had normal neutrophil counts had a response of 23.1%. Those that ended up neutropenic had no response to therapy.
The data were also analyzed to determine response rates after sequential antifungal therapy, combination therapy and continuation of prior antifungal therapy. Patients who stopped receiving itraconazole prior to the start of ABLC therapy had a clinical response rate of 28% (5/18), while those who started to receive itraconazole and ABLC concomitantly had a 29% response rate (4/14). None of the seven patients who continued prior itraconazole therapy after the start of ABLC had a clinical response. Table 3 shows renal function parameters, including baseline S-Cr and C cr and changes in S-Cr and C cr from baseline by the end of therapy, for patients receiving firstline and second-line ABLC treatment and overall for all Table 2 Clinical responses to ABLC treatment in allogeneic hematopoietic cell transplant recipients by neutrophil status at beginning and end of therapy 
Baseline S-Cr (mg/dl) Median patients. Median baseline S-Cr was highest (1.6 mg/dl; range 0.6-4.4 mg/dl), and median baseline C cr was lowest (58.4 ml/min; range 18.5-140 ml/min) in first-line ABLCtreated patients who had GVHD. However, at the end of therapy these patients demonstrated a median decrease in S-Cr from baseline (À0.2 mg/dl; range À3.2 to 0.3), and a median increase in C cr from baseline (32.5 ml/min; range À14.4 to 71.2). These results were significantly better than those for second-line ABLC-treated patients with GVHD (median S-Cr change from baseline, 0.5 mg/dl; range À0.5 to 4.3, P ¼ 0.003; median C cr change from baseline, À23.4 ml/min; range À69.4 to 20.9, P ¼ 0.003). In the overall patient population, S-Cr at the end of therapy increased a median 0.3 mg/dl from baseline (range À3.2 to 4.3 mg/dl) and C cr decreased a median 14.2 ml/min from baseline (range À71.1 to 71.2 ml/min). A total of 2% of the overall population developed a requirement for dialysis.
Discussion
IA continues to be associated with high mortality rates, particularly in HCT recipients, 3 and several recent prospective studies have investigated the clinical impact of newer formulations and classes of antifungal therapy on this disease. 11, [16] [17] [18] The data presented here are quite different from these studies in that they represent retrospectively captured data that reveal 'real-world' fungal infection management and outcomes assessments. The CLEAR database reflects a typical spectrum of patients treated for systemic fungal infections in North America, rather than the more selective populations commonly recruited for phase III clinical trials.
A limitation of the CLEAR database and therefore the present study is the absence of standardized definitions of fungal infections during the span of time data were collected for the CLEAR registry. Such definitions were later refined through collaborative efforts of the Invasive Fungal Infections Cooperative Group (IFICG) of the European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group (MSG). 19 Other shortcomings include a possible selection bias due to the fact that not all eligible patients were enrolled; the lack of objectively defined response data, and that long-term patient follow-up was not performed. In addition, clinicians were permitted to reduce ABLC dosing in patients registered in CLEAR and for those patients that may have developed early deterioration of renal function, therapy may have been discontinued before the fourth dose, thereby excluding them from the registry.
In the present study, allogeneic HCT recipients with IA who received ABLC had an overall response rate of 31% at the end of therapy. A subset of these patients without GVHD, showed a 34% response rate. However, as expected, the subset with GVHD had a poorer response rate (21%). Although direct comparison and statistical assessment is not possible, the overall 31% response rate was comparable to that reported in the Herbrecht et al study 11 for allogeneic HCT recipients treated with voriconazole for IA (32%), and appears better than that reported for AmB in the same study (13%). The response rates of first-line ABLC-treated patients would be a more appropriate comparison to the Herbrecht et al 11 study, since AMB and voriconazole were used as initial therapy and not as second-line salvage therapy in this reported prospective, comparative study. In the data presented here, the response rate in allogeneic HCT recipients was 41% when ABLC was used as initial therapy and 29% in second-line ABLC-treated patients. The most dramatic difference in response rates to first-line vs secondline ABLC therapy was observed in patients with GVHD. Of these patients, only 8% responded to ABLC as secondline therapy, while 44% responded to first-line ABLC treatment. Thus, despite the presence of GVHD, a risk factor for IA predicting a poor prognosis, first-line ABLC therapy resulted in a more favorable outcome.
Comparing AmB with another lipid formulation of the drug, amphotericin B colloidal dispersion (ABCD), in the treatment of IA in a group of immunocompromised patients including HCT recipients, Bowden et al 16 reported cured or improved response in only 18% (9/50) of all evaluable patients treated with ABCD. Patients with allogeneic HCT were not individually studied in the report and particularly those with GVHD would have been expected to show even poorer response.
Similar to the findings reported here, Wingard 18 found a 38% (11/29) response rate (cured or improved) among ABLC-treated HCT patients with IA. However, unlike the present study, 25% of patients were autologous HCT recipients, and may have contributed to an increased overall response rate. In addition, response rates in patients with GVHD were not individually studied and may be expected to have been lower than the overall rate.
The major risk and prognostic factors for IA after HCT are GVHD, corticosteroid therapy for GVHD, and neutropenia. The vast majority of cases of aspergillosis in our study population took place after engraftment (ie, after recovery from neutropenia). This is reflected in Table 2 where 71% (60/85) of HCT recipients were never neutropenic during the course of infection. They had the best response rate of 38.3%. Those who initially were neutropenic but by the end of therapy had normal neutrophil counts had a response rate of 23.1%. Those who ended up neutropenic by the end of therapy had no response to therapy. Thus, while neutrophil status at the end of therapy appears to be an important prognostic factor, it does not explain the improved response of first-line therapy nor the poor response of HCT recipients with GVHD as there were only 11 patients, (13%) who were neutropenic at end of therapy. And there were no patients with GVHD with neutropenia.
Despite the increased risk of renal dysfunction in patients with GVHD, renal function improved in first-line ABLCtreated patients, as shown by changes from baseline S-Cr and C cr , compared to second-line treated patients. Similarly, in the whole patient population, renal function was better at the end of first-line ABLC therapy than at the end of second-line treatment. These results confirm previous findings that ABLC is superior to AmB in terms of effects on renal function. 20, 21 There was no antagonism between antifungal agents when ABLC was started concomitantly with, or sequentially after, itraconazole therapy. 22 Interestingly however, none of seven patients responded when itraconazole was continued after ABLC was started. Since the patients in whom itraconazole was continued after ABLC treatment was started may have been the most seriously ill, selection bias may have accounted for the ineffectiveness of this treatment. Nevertheless, it is probably wise to discontinue itraconazole when starting ABLC therapy.
In summary, we report that ABLC, especially when administered as first-line therapy, can produce clinical response for IA even in the most immunocompromised patients, that is, HCT recipients with GVHD, with minimal effects on renal function.
